Gyre Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
Gyre Therapeutics, Inc. (GYRE) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 0 shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2026-03-13
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2024-06-30 was 2.12M shares.
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2024-03-31 was 2.12M shares.
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- Gyre Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2024 was 528.44K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares 10-K · filed 2026-03-13 | |||
| 2024-12-31 | 528.44K shares 10-K · filed 2026-03-13 | |||
| 2024-09-30 | 703.95K shares 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | 2.12M shares 10-Q · filed 2024-08-13 | 1.06M shares 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | 2.12M shares 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |